Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows
I'm PortAI, I can summarize articles.
Longeveron Inc. announced Phase 2 trial results showing its stem cell therapy, laromestrocel, reduces neuroinflammation in mild Alzheimer’s disease. Presented at the CTAD 2025, the therapy showed positive effects on hippocampal neuroinflammation and volume, supporting further development. This AI-generated news is informational and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments